Daily Chart

Send a Tweet

$NVS
#Novartis Ag-adr
NVS
Novartis Ag-adr
Look for:
NVS
Pre-Market Movers: $NVO,$FCL,$PCZ,$GSK,$ERTS,$HBC,$DDR,$DB,$GFA,$NVS...more
NVS
Novartis $NVS in-licenses a mid-to-late-stage experimental hepatitis C drug from a private Swiss co. Gains exclusive WW rights,except Japan.
NVS
Monday February 8 2010 MACD Sell Signal $ALXN $BAP $GILD $MCD $ROST $NVS $PETD $PII $LKFN $NTY #economics
NVS
@drpdtapp yes $NVS have Afinitor and $GSK have pazopanib. There are 6 approved in renal cc now
NVS
Getting ready for exclusive interview w/Roche CEO Severin Schwan @ 7:30a ET-ish on Squawk Box. $RHHBY $NVS (@mhuckman)
NVS
Getting ready for exclusive interview w/Roche CEO Severin Schwan @ 7:30a ET-ish on Squawk Box. Crew tweaking lights now. $RHHBY $NVS
NVS
Allergan’s Looking Real Pretty Right Now http://cnbc.com/id/35238576 $ABT $ACL $AGN $NVS #StockPicks #StockMarket
NVS
RT@MhuckmanRoche CEO Severin Schwan live 2mrw @ 7:30a ET-ish on "Squawk Box." 1st CNBC U.S. interview since buying Genentech. $RHH
NVS
Roche CEO Severin Schwan live 2mrw @ 7:30a ET-ish on "Squawk Box." 1st CNBC U.S. interview since buying Genentech. $RHHBY $NVS
NVS
Pfizer Earnings By the Numbers http://cnbc.com/id/35196988 $AMGN $BIIB $GENZ $GILD $MRK $NVS $PFE $WAT #StockMarket
NVS
$NVS $CSBTF Hypertension Market Will Be Constrained Through 2018 by Pipeline Containing Few Novel Emerging Therapies http://bit.ly/c3boXR
NVS
Is Genentech/Roche turning a blind eye to a marketing/PR opportunity for Lucentis/Avastin? Vote in the poll. http://bit.ly/9VSjxq $NVS
NVS
RT @adamfeuerstein: @mhuckman: Kaiser "real-world" study:Avastin = Lucentis for AMD. $NVS $RHHBY Genentech: Only L proven safe,eff
NVS
RT @mhuckman: BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucent
NVS
RT @mhuckman: Kaiser "real-world" study:Avastin works as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucentis proven safe
NVS
RT @mhuckman: BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucent
NVS
BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucentis proven safe
NVS
RT @mhuckman: FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.
NVS
RT @mhuckman: FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.
NVS
FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.




Novartis Ag-adr - NVS Insiders

No Insiders

We have no insiders for Novartis Ag-adr right now.

Know someone who is an insider on Novartis Ag-adr?
Let us know.

Novartis Ag-adr - NVS information

...
135,000 Employees
Last Reported Date: 07/17/14
Founded in 1895
Last $93.45 USD
Change Today +3.61 / 4.02%
Volume 4.1M
As of 12:08 PM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-adr (NVS) Snapshot

Open
$92.95
Previous Close
$89.84
Day High
$93.57
Day Low
$92.87
52 Week High
09/2/14 - $93.57
52 Week Low
10/10/13 - $72.77
Market Cap
252.9B
Average Volume 10 Days
974.8K
EPS TTM
--
Shares Outstanding
2.7B
EX-Date
02/27/14
P/E TM
--
Dividend
$2.76
Dividend Yield
2.96%
Request Investor Kit
NVS:US Advanced Stock Chart

novartis ag-adr (NVS) Related Bloomberg News

Fed Taper Question Keeps U.S. Corporate Bond Sales Below Average
Novartis Jury Awards $10.45 Million for Drug, Lawyer Says
Novartis’s Alcon Wins Bid to Block Apotex’s Generic Patanol
Teva’s Patents Infringed, U.S. Judge Rules
Risk Panel, Lloyds Capital, Pharma Overtime: Compliance

novartis ag-adr (NVS) Related News

Botox Maker Plans Deep Job Cuts During Takeover Fight
Who Should Pay the Bill for Wonder Drugs?
Big Pharma's Favorite Prescription: Higher Prices
Restrictions on Livestock Antibiotics Don't Worry the Drugmakers
[addPosition2]

novartis ag-adr (NVS) Key Developments

Novartis Reveals its Investigational Heart Failure Medicine, LCZ696

Novartis revealed that its investigational heart failure medicine, LCZ696, was superior to ACE-inhibitor enalapril on key endpoints in the heart failure study ever done. In PARADIGM-HF, patients with heart failure with reduced ejection fraction (HF-REF) who were given LCZ696 were more likely to be alive and less likely to have been hospitalized for sudden deterioration of their heart failure than those given ACE-inhibitor enalapril. Patients received LCZ696 or enalapril on top of current best treatment. The magnitude of benefit with LCZ696 against enalapril in HF-REF patients was highly statistically significant and clinically important. In the study, the benefit of LCZ696 was seen early, was sustained and was consistent across subgroups. LCZ696: reduced the risk of death from cardiovascular (CV) causes by 20% (p=0.00004); reduced heart failure hospitalizations by 21% (p=0.00004); reduced the risk of all-cause mortality by 16% (p=0.0005). Overall there was a 20% risk reduction on the primary endpoint, a composite measure of CV death or heart failure hospitalization (p=0.0000002). LCZ696, a twice a day tablet being investigated for heart failure, has a unique mode of action which is thought to reduce the strain on the failing heart. It acts to enhance the protective neurohormonal systems of the heart (NP system) while simultaneously suppressing the harmful effects of the overactive RAAS (renin-angiotensin-aldosterone system). Currently available medicines for HF-REF work only to block the detrimental effects. Despite existing therapies, the mortality rate remains very high with up to 50% of patients dying within 5 years of a diagnosis of heart failure. Approximately half of patients with heart failure have HF-REF. Analysis of the safety data from PARADIGM-HF showed side effects were manageable in the study. Fewer patients on LCZ696 discontinued study medication for any adverse event compared to those on enalapril (10.7% vs. 12.3%, respectively; p=0.03). The LCZ696 group had more hypotension and non-serious angioedema but less renal impairment, hyperkalemia and cough than the enalapril group. The most common adverse events with LCZ696 (incidence >=10%) compared to enalapril were elevated serum potassium of more than 5.5 mmol/liter (16.1% vs. 17.3%), symptomatic hypotension (14.0% vs. 9.2%) and cough (11.3% vs. 14.3%). Novartis plans to file the New Drug Application for review with the US FDA by the end of 2014.

Pharmstandard to Start Local Production of Novartis's Oncology Drug Tasigna

Pharmstandard announced that it has concluded an agreement with Novartis for the localisation of the production of the latter's oncology drug Tasigna. The drug will be manufactured at the company's facility in Ufa, Bashkiria. The source adds that Pharmstandard will also promote and sell Tasigna in Russia. Tasigna is indicated for the treatment of Philadelphia Chromosome positive chronic myeloid leukaemia in adults.

Novartis Provides Drug Candidate Compounds to TB Alliance

Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance) for compounds to fight tuberculosis (TB) that have been discovered at the Novartis Institutes for Tropical Diseases (NITD). Under the terms of agreement, NITD will fully transfer its TB research and development program to TB Alliance, which will take financial and operational responsibility for continued research, development, approval and distribution of compounds in the portfolio. Included is a novel class of drugs called indolcarboxamides that are active against drug sensitive and multi-resistant strains of TB. One of these preclinical compounds NITD304, blocks MmpL3, a protein essential for the TB bacterium's survival.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $93.45 USD +3.61

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Johnson & Johnson $103.25 USD -0.48
Merck & Co Inc $59.84 USD -0.27
Pfizer Inc $29.31 USD -0.08
Roche Holding AG SFr.268.90 CHF -0.40
Procter & Gamble Co/The $83.03 USD -0.085
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 24.1x
Price/Sales 3.7x
Price/Book 3.1x
Price/Cash Flow 24.9x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Novartis Ag-adr - NVS news

3 Mega-Cap Dividend Stock Ideas

Quote:
Read article

US doctor pleads guilty in securities case

Keywords: US doctor pleads guilty in securities case, nvs, pe-and-hedgefunds
Quote:
Read article

Awaiting Novartis acquisition, biotech firm Proteon raises $15.2M

Quote:
Read article

Will Investors Regret Leaving The US?

Keywords: ETFs,Investing,Markets,Stocks,Business,Exchange-traded fund,Forbes,IShares,Research and Analysis,Shares outstanding,Trade
Quote:
Read article

LEAD 1-Nestlé porté par la croissance dans les pays émergents

Quote:
Read article

UPDATE 1-Vectura extends VR315 deal with Sandoz to new areas

Keywords: United States, Will Waterman
Quote:
Read article

Momenta's earnings rise on market grab from Sanofi

Quote:
Read article

[$$] Novartis' MS Pill Questioned by U.K. Regulator

Quote:
Read article

9 Swiss Stocks That May Be a Haven

Quote:
Read article

Advisers steer clients to safer havens in stormy market

Keywords: Greece, Italy, Switzerland, RichardSatran, S&P 500
Quote:
Read article

Vanda Pharmaceuticals reports loss

Quote:
Read article

Swiss stocks - Factors to watch on Aug 5

Quote:
Read article

FDA: Generic biotech drugs require paradigm shift

Keywords: Israel, United States, Michele Gershberg, Phil Berlowitz
Quote:
Read article

UPDATE 2-Vectura gets new U.S. partner for copy of lung drug

Keywords: United States, Andrew Callus
Quote:
Read article

UPDATE 1-Vectura strikes new U.S. deal for lung drug VR315

Keywords: United States
Quote:
Read article

UPDATE 1-Finnish drug maker Orion Q2 meets forecast

Keywords: Switzerland, Jane Merriman
Quote:
Read article

Vanda aims for Argentina

Quote:
Read article

Buyout firms to bid for GSK drugs portfolio-sources

Keywords: Britain, Jane Merriman
Quote:
Read article

PDL posts bigger 2Q profit on lower legal costs

Keywords: PDL posts bigger 2Q profit on lower legal costs, nvs,pdli, earnings
Quote:
Read article

Flu "super antibody" may bring universal shot closer

Quote:
Read article
Stocktweeting is not a financial advisor, and in no way recommends the purchase of any stock or advise on the suitability of any trade or investment.
Stock trading and investing can cause loss of capital, and you should always consult with a professional financial advisor before trading or investing.

This website is a service of the HagensMedia ad network. For advertising please visit http://www.hagensmedia.com - Copyright 2011-2012.